NASDAQ: INCY
Incyte Corp Stock

$74.95-0.31 (-0.41%)
Updated Feb 6, 2025
INCY Price
$74.95
Fair Value Price
$126.20
Market Cap
$14.44B
52 Week Low
$50.35
52 Week High
$83.95
P/E
440.88x
P/B
4.55x
P/S
3.12x
PEG
1.65x
Dividend Yield
N/A
Revenue
$4.08B
Earnings
$32.48M
Gross Margin
92.8%
Operating Margin
6.78%
Profit Margin
0.8%
Debt to Equity
0.58
Operating Cash Flow
$102M
Beta
0.61
Next Earnings
Feb 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A

INCY Overview

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine INCY's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More

Zen Rating Component Grades

B
Value
B
Growth
C
Momentum
C
Sentiment
B
Safety
B
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
INCY
Ranked
#24 of 560

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important INCY news, forecast changes, insider trades & much more!

INCY News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

INCY ($74.95) is undervalued by 40.61% relative to our estimate of its Fair Value price of $126.20 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
INCY ($74.95) is significantly undervalued by 40.61% relative to our estimate of its Fair Value price of $126.20 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
INCY ($74.95) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INCY due diligence checks available for Premium users.

Valuation

INCY fair value

Fair Value of INCY stock based on Discounted Cash Flow (DCF)

Price
$74.95
Fair Value
$126.20
Undervalued by
40.61%
INCY ($74.95) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INCY ($74.95) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INCY ($74.95) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

INCY price to earnings (PE)

For valuing profitable companies with steady earnings

Company
440.88x
Industry
-152.12x
Market
31.69x
INCY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INCY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

INCY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.55x
Industry
5.03x
INCY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

INCY price to earnings growth (PEG)

For valuing profitable companies with growth potential

INCY is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

INCY's financial health

Profit margin

Revenue
$1.1B
Net Income
$106.5M
Profit Margin
9.4%
INCY's Earnings (EBIT) of $276.53M... subscribe to Premium to read more.
Interest Coverage Financials
INCY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$5.0B
Liabilities
$1.8B
Debt to equity
0.58
INCY's short-term assets ($2.81B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INCY's short-term assets ($2.81B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INCY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$310.9M
Investing
$38.3M
Financing
-$32.4M
INCY's operating cash flow ($101.85M)... subscribe to Premium to read more.
Debt Coverage Financials

INCY vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
INCYB$14.44B-0.41%440.88x4.55x
INSMC$14.45B-0.82%-14.55x29.90x
SMMTC$15.24B-0.53%-10,335.00x34.81x
UTHRB$15.79B-0.12%14.55x2.59x
MRNAC$12.93B-3.92%-5.78x1.08x

Incyte Stock FAQ

What is Incyte's quote symbol?

(NASDAQ: INCY) Incyte trades on the NASDAQ under the ticker symbol INCY. Incyte stock quotes can also be displayed as NASDAQ: INCY.

If you're new to stock investing, here's how to buy Incyte stock.

What is the 52 week high and low for Incyte (NASDAQ: INCY)?

(NASDAQ: INCY) Incyte's 52-week high was $83.95, and its 52-week low was $50.35. It is currently -10.72% from its 52-week high and 48.86% from its 52-week low.

How much is Incyte stock worth today?

(NASDAQ: INCY) Incyte currently has 192,650,249 outstanding shares. With Incyte stock trading at $74.95 per share, the total value of Incyte stock (market capitalization) is $14.44B.

Incyte stock was originally listed at a price of $22.50 in Dec 31, 1997. If you had invested in Incyte stock at $22.50, your return over the last 27 years would have been 233.11%, for an annualized return of 4.56% (not including any dividends or dividend reinvestments).

How much is Incyte's stock price per share?

(NASDAQ: INCY) Incyte stock price per share is $74.95 today (as of Feb 6, 2025).

What is Incyte's Market Cap?

(NASDAQ: INCY) Incyte's market cap is $14.44B, as of Feb 7, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Incyte's market cap is calculated by multiplying INCY's current stock price of $74.95 by INCY's total outstanding shares of 192,650,249.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.